IPC adds these 9 new IP impurities standards

Impurity standards are used to perform the system suitability, qualitative and quantitative parameters for compliance with the Indian Pharmacopoeia monograph.

148
IPC
Representational image

Last Updated on December 8, 2021 by The Health Master

The Indian Pharmacopoeia Commission (IPC) has added nine new IP impurities standards, which include:

  • Bromhexine Hydrochloride Impurity C,
  • Cabergoline Impurity A,
  • Cilostazol Impurity B,
  • Citalopram Impurity B,
  • Fosinopril Impurity A,
  • O-toluene sulfonamide,
  • P-toluene sulfonamide,
  • Tributyl o-acetyl citrate/Acetyl Tributyl citrate,
  • Vildagliptin Impurity D.

Impurity standards are used to perform the system suitability, qualitative and quantitative parameters for compliance with the Indian Pharmacopoeia monograph.

The commission stated that certain monographs require the use of a chemical reference substance or a biological reference preparation or a reference spectrum.

As a part of the Capability Building initiative, IPC in collaboration with USP, also conducted a webinar on “Fundamentals of Dissolution” as a part of the Capability Building initiative. The webinar was conducted “exclusively” for MSME (micro, small and medium enterprises).

The session, conducted by Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC and Josan Thomas, Scientific Liaison, USP India, covered the science behind dissolution, fundamentals of dissolution testing, and specifics related to the qualification of USP apparatus 1 and apparatus 2. The session saw a great response with 339 participants from 149 unique companies.

The panelists for the webinar include:

  • Dr. Rajeev Singh Raghuvanshi – Secretary-cum-Scientific Director, IPC,
  • Dr. Robin Kumar – Principal Scientific Officer,
  • Dr. Gaurav Pratap Singh Jadaun – Senior Scientific Officer, IPC,
  • Josan Thomas, Scientific Liaison, USP India,
  • Mr. Girish Kapur- Vice President, USP India,
  • Joseph Eaton – Senior Manager, USP Rockville.

The vision of IPC is to promote the highest standards of drugs for use in humans and animals within the practical limits of the technologies available for manufacture and analysis.

IPC is an autonomous institution of the ministry of health and family welfare, government of India. The IPC was created to set standards for drugs in the country.

Its basic function is to regularly update the standards of drugs commonly required for the treatment of diseases prevailing in this region.

The mandate of the commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis, besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues.

Latest Circulars: (IPC) Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

Latest on National Formulary of India (NFI)

68 cases of unapproved Fixed Dose Combinations reported during 2017-21

Drug recall: Aurobindo, Unichem recall these drugs from the market

Scientists developing chewing gum that could reduce Virus transmission

100 crore drug racket: Accused transported drugs in vehicle with Chandigarh number plate

NPPA fixes retail price of 2 formulations: November 2021

Procedure to obtain license for Commercial Testing Laboratories

NPPA to hire 33 professionals for various levels of its operations

Govt to amend Drug Rules for list of colours permitted to…

NPPA fixes retail price of 47 formulations: November 2021

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner